A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
NCT #
NCT02912949
Condition(s)
Lung Cancer (NSCLC), Pancreatic Cancer
Molecular Target(s)
HER2, HER3
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
any treatments that use the protein folate receptor alpha or FRĪ± to work
Phase(s)
I/II
Mechanism of Action
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Purpose
n/a
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.